Abstract:AIM: To investigate the effects of Bevacizumab on the proliferation and the expression of E-Cadherin and fibronectin in human retinal pigment epithelial cell(ARPE-19)in vitro.
METHODS: Different concentrations(0, 0.625, 1.25, 2.5, 5.0mg/mL)of bevacizumab were exposed to ARPE-19 cells, then cell viability was analyzed by CCK-8, cell cycle was determined by flow cytometry, and the expression of E-Cadherin and fibornectin was detected by Western blot and RT-PCR.
RESULTS: The concentration as 2.5mg/mL or 5.0mg/mL of bevacizumab was shown to effectively suppress the proliferation and cell cycle of ARPE-19 cell(P<0.05). In addition, 2.5mg/mL or 5.0mg/mL of bevacizumab could downregulate the expression of E-cadherin and promote the transcription of fibronection gene(P<0.05).
CONCLUSION: High concentration of bevacizumab was able to inhibit ARPE-19 proliferation, downregulate E-Cadherin expression and promote fibronectin expression, indicating epithelial-mesenchymal transition induced by bevacizumab in ARPE-19 cell.
